Pure Global
NCT03372057

A Study of Duvelisib in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL)

A Multi-Center, Phase 2, Open-label, Parallel Cohort Study of Efficacy and Safety of Duvelisib in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL)
SecuraBio·Phase 2·ClinicalTrials.gov·drugActive, not recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Peripheral T-cell Lymphoma
Drug/Device/Intervention
Duvelisib
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
SecuraBio
Location
Duarte,Irvine,Los Angeles,Atlanta,Chicago,Louisville,Baltimore,Boston,Saint Louis,New York,Rochester,Stony Brook,Charlotte,Charlotte,Durham,Columbia,Toledo,Pittsburgh,Dallas,Halle,Dresden,Bergamo,Bolo, Germany,Italy,United Kingdom,United States of America
Timeline & enrollment
Phase
Phase 2
Start date
Feb 22, 2018
End date
Dec 01, 2024
Enrollment
120 participants
Primary outcome

Objective response rate (ORR)

Summary

This is a multi-center, parallel cohort, open-label, Phase 2 study of duvelisib, an oral dual
 inhibitor of PI3K-δ,γ, in patients with relapsed or refractory Peripheral T cell Lymphoma
 (PTCL).

ICD-10 classifications
Peripheral T-cell lymphoma, not elsewhere classifiedCutaneous T-cell lymphoma, unspecifiedMature T/NK-cell lymphomasAngioimmunoblastic T-cell lymphomaOther mature T/NK-cell lymphomas
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT03372057
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT03372057 through Pure Global AI's free database. This Phase 2 trial is sponsored by SecuraBio and is currently Active, not recruiting. The study focuses on Peripheral T-cell Lymphoma. Target enrollment is 120 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.